Abstract
Allergic contact dermatitis (ACD) is an increasing health problem with limited treatment options. We describe here our recent findings showing that Transient Receptor Potential Ankyrin 1 (TRPA1) mediates DNCB-induced contact dermatitis in experimental models. The results support TRPA1 as a drug target to prevent/treat ACD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
